欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > GPCR/GProtein > LIXIVAPTAN

浏览历史

S83858

LIXIVAPTAN

源叶(MedMol) 99%
  • 英文名:
  • LIXIVAPTAN
  • 别名:
  • 利伐普坦;利昔伐坦;LIXIVAPTAN;N-[3-Chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methylbenzamide;VPA 985;BenzaMide,N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11
  • CAS号:
  • 168079-32-1
  • 分子式:
  • C27H21ClFN3O2
  • 分子量:
  • 473.926
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S83858-2mg 99% ¥192.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S83858-5mg 99% ¥385.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S83858-10mg 99% ¥650.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S83858-25mg 99% ¥1110.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S83858-50mg 99% ¥1780.00元 预计交期:2-3天 - - - EA 加入购物车
源叶(MedMol) S83858-100mg 99% ¥2800.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 提示:详情请下载说明书。
  • 产品描述: Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively.
  • 靶点: IC50: 1.2 nM (human V2), 2.3 nM (rat V2);VasopressinReceptor
  • 体内研究:
    In conscious dogs, water-loaded with 30 mL/kg (po) and arginine vasopressin (AVP)-treated (0.4 µg/kg in oil, sc), lixivaptan (1, 3, and 10 mg/kg po) increases Uvol over the AVP-treated vehicle group by 438, 1018, and 1133%, respectively, while Uosm decreases from 1222 mOsm/kg (water-loaded and AVP treated vehicle) to 307, 221, and 175 mOsm/kg, respectively. In homozygous Brattleboro rats lacking AVP, lixivaptan at 10 mg/kg po (i.e., 10 times the dose producing V2 antagonist activity) b.i.d. for 5 days, shows a sustained antagonist action without evidence of agonist effects. In a randomized double-blind placebo-controlled ascending single dose study, patients (deprived of fluids overnight before dosing) are dosed orally with 30, 75, or 150 mg of lixivaptan. All three doses increase urine flow and serum sodium concentrations and produced significant dose-related decreases in urinary osmolality. Phase II clinical trials in patients with congestive heart failure, liver cirrhosis with ascites or syndrome of inappropriate antidiuretic hormone have demonstrated that lixivaptan increases water clearance without affecting renal sodium excretion or activating the neurohormonal system
  • 参考文献:
    1. Albright JD, et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem. 1998 Jul 2;41(14):244 2. Ghali JK, et al. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia. IDrugs. 2010 Nov;13(11):782-92.
  • 溶解性: Soluble  in  DMSO
  • 保存条件: 2-8℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.11 ml 10.55 ml 21.1 ml
    5 mM 0.422 ml 2.11 ml 4.22 ml
    10 mM 0.211 ml 1.055 ml 2.11 ml
    50 mM 0.042 ml 0.211 ml 0.422 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。